The PARP1–JAK2–STAT3 signaling axis as a central molecular driver of penile carcinoma (DGU 2026) - Oct 15, 2026 - Abstract #V01-06; Pres time: Sep 16, 2026; 11:20 AM - 11:30 AM; Location: Room 6; "Cisplatin- and osimertinib-resistant penile carcinoma cell lines were generated and compared with parental cell lines. Pharmacological inhibition was achieved using PARP inhibitors (olaparib, saruparib), fedratinib (JAK2), and napabucasin (STAT3)... These data underscore the central role of the PARP1–JAK2–STAT3 axis in progression and resistance development in PeCa."
Genito-urinary Cancer • Oncology • Penile Cancer • Solid Tumor • CCND1 • KDR • MMP2
|
|
A. Thomas 1; K. Slade 1; N. Ries 1; A. Haferkamp 1; P. Stenzel 2; I. Tsaur 3
|